...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical and laboratory haematology >Nonchemotherapy drug-induced agranulocytosis: experience of the Strasbourg teaching hospital (1985-2000) and review of the literature.
【24h】

Nonchemotherapy drug-induced agranulocytosis: experience of the Strasbourg teaching hospital (1985-2000) and review of the literature.

机译：非化学疗法引起的粒细胞缺乏症：史特拉斯堡教学医院的经历（1985-2000年）和文献复习。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Agranulocytosis is a life-threatening disorder that frequently occurs as an adverse reaction to drugs. The overall incidence of nonchemotherapy drug-induced agranulocytosis (DIA) ranges from 2.6 to 10 cases per million patients exposed to drugs per year. Although patients experiencing DIA may initially be asymptomatic, the severity of the neutropenia usually leads to severe sepsis, requiring intravenous broad-spectrum antibiotic therapy. In this setting, old age, septicaemia, shock, and the metabolic complications of infection, such as renal failure, are poor prognostic variables. The severity of neutropenia (< 0.1 x 109/l) and its duration (> 10 days) may also impact negatively on the outcome. With appropriate management using pre-established procedures, the mortality rate is now around 5%. Haematopoietic growth factors have been shown to shorten the duration of neutropenia in DIA. However, it has yet to be determined whether their use translates into a better outcome in DIA patients experiencing sepsis. DIA still remains a rare event. However, given the increased life expectancy and subsequent longer exposure to drugs, as well as the development of new agents, physicians should be aware of this complication and its management.
机译：粒细胞缺乏症是危及生命的疾病，经常作为对药物的不良反应而发生。非化学药物引起的粒细胞缺乏症（DIA）的总发生率范围为每年每百万接触药物的患者2.6至10例。尽管患有DIA的患者最初可能没有症状，但中性粒细胞减少症的严重程度通常会导致严重的败血症，因此需要静脉内广谱抗生素治疗。在这种情况下，老年，败血病，休克和感染的代谢并发症（如肾衰竭）是不良的预后变量。中性粒细胞减少症的严重程度（<0.1 x 109 / l）及其持续时间（> 10天）也可能对结果产生负面影响。通过使用预先建立的程序进行适当的管理，死亡率现在可以达到5％左右。造血生长因子已显示可缩短DIA中性粒细胞减少的持续时间。但是，尚需确定在患有败血症的DIA患者中，使用它们是否能改善患者的预后。 DIA仍然是罕见的事件。但是，鉴于预期寿命的延长和随后对药物的接触时间更长，以及开发新的药物，医生应意识到这种并发症及其处理方法。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号